INCY

114.6251.07%
PJ

Pablo J. Cagnoni

President and Global Head of R&D

Dr. Pablo J. Cagnoni, M.D., Ph.D. is Director of Sail Biomedicines, Inc. Dr. Cagnoni is President of Incyte and Global Head of R&D of Incyte Corporation from May 2026 and served as its President and Global Head of Research & Development from May 2023 to May 2026. Dr. Cagnoni joined the Incyte Corporation in May 2023. He is a Executive Partner at November 11, 2022. He serves as Director at Trishula Therapeutics Inc. He is a Director at Turmeric Acquisition Corp. and Repertoire Immune Medicines, Inc. He serves as Director at LARONDE, Inc. since November 2021 and served as its Chief Executive Officer since November 2022. He is Director of Synthekine, Inc. since Februay 2021. Dr. Cagnoni had been the Chief Executive Officer of Rubius Therapeutics, Inc. since June 06, 2018 until November 15, 2022 and was its Director from June 6, 2018 to April 6, 2023 and also served as its President until November 15, 2022 and was its Chairman from November 2, 2022 to April 6, 2023. He serves as Independent Director at Fusion Pharmaceuticals Inc. since December 1, 2019. From April 2018 to June 2018, Dr. Cagnoni served as an advisor at Rubius Therapeutics, Inc. Dr. Cagnoni currently serves on the Board of Trustees for the Bay Area Discovery Museum and is a member of the Council on Foreign Relations. He Co-Founded of Tizona Therapeutics, Inc. and served as its Chief Executive Officer and President from May 2015 to June 2018. He is the Executive Chairman of Blade Therapeutics. He served as a Managing Director at MPM Capital from May 20, 2015 until 2016. He served as the President of Onyx Pharmaceuticals, Inc. from October 2013 to 2015, where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Dr. Cagnoni joined Onyx in March 2013 as an Executive Vice President of Global Research & Development and Technical Operations. At Onyx, he had global strategic oversight and accountability of the business from early product development to commercialization. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology, where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. He served as the Chief Medical Officer and Senior Vice President of Allos Therapeutics, Inc. from March 20, 2007 to September 30, 2009. He led Allos Therapeutics Inc.’s clinical development functions, including clinical operations, medical affairs and biometrics. From 2004 to 2007, he held several key management positions with OSI Pharmaceuticals, Inc. served as the Chief Medical Officer and Vice President of Clinical Research and Medical Affairs since December 18, 2006. He serves as Executive Partner at Flagship Pioneering until May 2023. He oversaw all of the clinical development and medical affairs activities of OSI Pharmaceuticals’s oncology portfolio which includes further development of its flagship product Tarceva. He served as Vice President of Medical Affairs, Clinical Development and Translational Research of Osi Pharmaceuticals Inc. and served as an Interim Senior Medical Officer For Oncology Clinical Development since May 1, 2005. He served as Allos Therapeutics, Inc.’s Consultant for clinical development and regulatory activities since August 2004. He served at Allos Therapeutics Inc. as Vice President of Clinical Development from March 2003 to August 2004 and served as Senior Medical Director from June 2002 to February 2003 and as a Director of Clinical Development from July 2001 to June 2002. Prior to Allos Therapeutics Inc. he served as an Assistant Professor of Medicine in the Division of Oncology at the University of Colorado, where he also served as an Assistant Director of the Pharmacology Laboratory and Member of the Bone Marrow Transplant Program and a Member of the University of Colorado Cancer Center. He has been a Director of Lycera Corp. since March 13, 2017. Dr. Cagnoni served as a Director of Harpoon Therapeutics. He served as an Independent Director of CRISPR Therapeutics AG from December 2015 to February 26, 2020. He also served as a Director of Tizona Therapeutics, Inc. until March 2021. Dr. Cagnoni earned his M.D. from the University Buenos Aires School of Medicine and he completed his fellowship in Hematology and Oncology at The Mount Sinai Medical Center, New York and in Bone Marrow Transplantation at the University of Colorado. Dr. Cagnoni completed a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center. Dr. Cagnoni received an M.D. from the University of Buenos Aires School of Medicine and completed post-doctoral work in Hematology and Oncology at the Mount Sinai Medical Center in New York and in Stem Cell Transplantation at the University of Colorado Health Sciences Center. Dr. Cagnoni serves as Director of Laronde Therapeutics.

Positions